Our Science

Genbioma’s research and development is focused on the microbiome, the trillions of microorganisms that inhabit the human gut. Hundreds of scientific studies published over the last two decades have established a solid connection between the composition and the activity of the microbiome and human physiology, in particular with metabolic health.

Genbioma’s platform exploits the cross-communication mechanisms between the human body and its symbiotic microbes to improve human health.

Product Development Platform

Genbioma has built a science-based product development platform that yields probiotics and postbiotics for multiple health applications.

Starting from Genbioma’s proprietary microbial strain collection, as well as other culture collections, each strain is subjected to a rational, mechanism-based, step-wise process that optimizes every step of R&D efforts to deliver highest-quality food active ingredients.

Genbioma’s platform’s lead product is pA1c®HI, a heat-treated postbiotic derived from the bacterial strain pA1c®, with multiple applications in metabolic health.

Other strains for different applications are currently under development.

Health Solutions

Genbioma’s initial focus is metabolic health, mainly glucose control, lipid metabolism and weight reduction. Today, pA1c®HI has been subjected to 9 clinical and preclinical trials.

Prediabetes

Prediabetes is a metabolic condition in which blood sugar levels are elevated, but still below the threshold for the diagnosis of Type 2 diabetes. If not dealt with, prediabetes leads to Type 2 diabetes. Whereas Type 2 diabetes is irreversible and requires lifelong management, prediabetes may be reversible if properly managed.

It is estimated that around 350 million people are currently prediabetic in the world, and the number is anticipated to increase to almost 600 million people by 2045.

pA1c®HI’s efficacy has been clinically demonstrated. Human data has shown that, in just 3 months of daily consumption, pA1c®HI is able to improve risk factors directly related to the development of type-2 diabetes from prediabetes, namely:

Significantly reduce glycosylated hemoglobin levels by 0.22%.by 0.22%.
Produce beneficial, clinically relevant changes for glycemia (11.8%), basal insulin levels (50.2%) and HOMA-IR index (60.3%).
Significantly reduce the total weight, BMI and fat mass.

Type 2 Diabetes

Diabetes is a chronic metabolic disease characterized by elevated blood sugar levels which, with time, damages the heart, blood vessels, eyes, kidneys and nerves. Its most common type is Type 2 diabetes, which happens when the body becomes resistant to insulin or does not make enough insulin.

Currently, over 400 million people live with diabetes worldwide and about 1.5 million annual deaths are attributable to diabetes. The prevalence of the disease has been rapidly growing over the last decades.

pA1c®HI’s effects have been demonstrated in different preclinical studies, which support the postbiotic efficacy. Studies performed on type 2 diabetic mice models has shown that pA1c®HI:

Reduction in Fasting Blood Glucose by almost 50% compared to control mice, demonstrating its efficacy in improving glycemic control.
Significantly decrease body weight gain by 30% and total body weight by 40% compared to control.
Significantly increase GLP-1 colonic area by 46% and decrease serum leptin 30-fold compared to control.

Scientific Publications

Pediococcus acidilactici CECT 9879 (pA1c®) and heat inactivated pA1c® (pA1c® HI) ameliorate gestational diabetes mellitus in mice

Link to publication

Postbiotic pA1c®HI reduces weight and glycemia in prediabetic obese individuals.

A randomized, double-blind, controlled nutritional intervention

Link to publication

Heat-inactivated Pediococcus acidilactici pA1c®HI maintains glycaemic control and prevents body weight gain in high-fat diet-fed mice

Link to publication

Pediococcus acidilactici (pA1c®) alleviates obesity-related dyslipidemia and inflammation in Wistar rats by activating beta-oxidation and modulating the gut microbiota